Trial · NCT03993132
Outcomes14
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Incidence Rate of Expanded Major Adverse Cardiovascular Event (MACE) Composite Outcome - OT Analysis | From first initiation of empagliflozin or liraglutide until end of follow-up, up to 6 years. | All patients included in the propensity score (PS) balanced cohort of either empagliflozin or liraglutide users. | Events per 1000 person-years | NUMBER |
| PRIMARY | Incidence Rate of Expanded Major Adverse Cardiovascular Event (MACE) Composite Outcome - ITT Analysis | From first initiation of empagliflozin or liraglutide until end of follow-up, up to 6 years. | All patients included in the propensity score (PS) balanced cohort of either empagliflozin or liraglutide users. | Events per 1000 person-years | NUMBER |
| SECONDARY | Incidence Rate of Heart Failure (HF) Hospitalization or All-cause Death - OT Analysis | From first initiation of empagliflozin or liraglutide until end of follow-up, up to 6 years. | All patients included in the propensity score (PS) balanced cohort of either empagliflozin or liraglutide users. | Events per 1000 person-years | NUMBER |
| SECONDARY | Incidence Rate of Heart Failure (HF) Hospitalization or All-cause Death - ITT Analysis | From first initiation of empagliflozin or liraglutide until end of follow-up, up to 6 years. | All patients included in the propensity score (PS) balanced cohort of either empagliflozin or liraglutide users. | Events per 1000 person-years | NUMBER |
| SECONDARY | Incidence Rate of First Hospitalized Heart Failure (HHF) or Initiation of Community Prescription Drug Therapy With Loop Diuretics - OT Analysis | From first initiation of empagliflozin or liraglutide until end of follow-up, up to 6 years. | All patients included in the propensity score (PS) balanced cohort of either empagliflozin or liraglutide users. | Events per 1000 person-years | NUMBER |
| SECONDARY | Incidence Rate of First Hospitalized Heart Failure (HHF) or Initiation of Community Prescription Drug Therapy With Loop Diuretics - ITT Analysis | From first initiation of empagliflozin or liraglutide until end of follow-up, up to 6 years. | All patients included in the propensity score (PS) balanced cohort of either empagliflozin or liraglutide users. | Events per 1000 person-years | NUMBER |
| SECONDARY | Incidence Rate of All-cause Hospitalization or Death - OT Analysis | From first initiation of empagliflozin or liraglutide until end of follow-up, up to 6 years. | All patients included in the propensity score (PS) balanced cohort of either empagliflozin or liraglutide users. | Events per 1000 patient years | NUMBER |
| SECONDARY | Incidence Rate of All-cause Hospitalization or Death - ITT Analysis | From first initiation of empagliflozin or liraglutide until end of follow-up, up to 6 years. | All patients included in the propensity score (PS) balanced cohort of either empagliflozin or liraglutide users. | Events per 1000 patient years | NUMBER |
| SECONDARY | Incidence Rate of All Cause Hospitalization - OT Analysis | From first initiation of empagliflozin or liraglutide until end of follow-up, up to 6 years. | All patients included in the propensity score (PS) balanced cohort of either empagliflozin or liraglutide users. | Events per 1000 patient years | NUMBER |
| SECONDARY | Incidence Rate of All Cause Hospitalization - ITT Analysis | From first initiation of empagliflozin or liraglutide until end of follow-up, up to 6 years. | All patients included in the propensity score (PS) balanced cohort of either empagliflozin or liraglutide users. | Events per 1000 patient years | NUMBER |
| SECONDARY | Incidence Rate of All-cause Death - OT Analysis | From first initiation of empagliflozin or liraglutide until end of follow-up, up to 6 years. | All patients included in the propensity score (PS) balanced cohort of either empagliflozin or liraglutide users. | Events per 1000 patient-years | NUMBER |
| SECONDARY | Incidence Rate of All-cause Death - ITT Analysis | From first initiation of empagliflozin or liraglutide until end of follow-up, up to 6 years. | All patients included in the propensity score (PS) balanced cohort of either empagliflozin or liraglutide users. | Events per 1000 patient-years | NUMBER |
| SECONDARY | Incidence Rate of Hospitalization for Heart Failure (HF) - OT Analysis | From first initiation of empagliflozin or liraglutide until end of follow-up, up to 6 years. | All patients included in the propensity score (PS) balanced cohort of either empagliflozin or liraglutide users. | Events per 1000 patient years | NUMBER |
| SECONDARY | Incidence Rate of Hospitalization for Heart Failure (HF) - ITT Analysis | From first initiation of empagliflozin or liraglutide until end of follow-up, up to 6 years. | All patients included in the propensity score (PS) balanced cohort of either empagliflozin or liraglutide users. | Events per 1000 patient years | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03993132/outcomes